Navigation Links
MGH Neurological Clinical Research Institute and Prize4Life receive Bio-IT World award
Date:4/12/2013

The Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) and Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for amyotrophic lateral sclerosis (ALS), received a Best Practices Award at the 2013 Bio-IT World Conference & Expo. Presented on April 10, the award acknowledged the creation of the Pooled Resource Open-access ALS Clinical Trials (PRO-ACT) platform.

The PRO-ACT platform was chosen from 33 detailed submissions for the Bio IT World award and was honored in the "Clinical & Health IT" category. The dynamic database helps to accelerate discovery, development and delivery of future ALS treatments by housing the largest dataset from completed Phase II and III clinical trials in ALS. The platform enables the merging of data from global clinical trials, generating a valuable resource for the design of future trials and the identification of novel correlations and disease biomarkers.

The PRO-ACT database, contains more than 8,500 fully deidentified, unique clinical patient records both treatment and placebo data from 17 late-stage industry and academic trials and over 8 million data points, including 1.7 million records of lab test results of ALS patients. "The results garnered through the use of the PRO-ACT platform will benefit more than just the scientific and medical research fields; they will also impact ALS patients and their families, potentially by giving them answers to their currently unanswerable questions," states Alexander Sherman, NCRI director of Systems and a pioneering force behind the launch. "It is an unprecedented opportunity to increase the field's understanding of the ALS patient population and the natural history of the disease."

Melanie Leitner, PhD, Prize4Life chief scientific officer says, "We have been thrilled at the ALS community's enthusiastic response to PRO-ACT since its December 2012 launch, including 117 requests to access the PRO-ACT data from industry, clinicians, biostatisticians and other quantitative experts. It is our belief that open access to this rich treasure of data will attract new ideas and shed new light on this disease. We thank Bio-IT World for the opportunity provided by this award to bring PRO-ACT to the attention of the larger Bio-IT community."

NCRI and Prize4Life created the PRO-ACT database with funding from the ALS Therapy Alliance (http://alstherapyalliance.org) in partnership with the Northeast ALS Consortium (http://www.alsconsortium.org/). Academic institutions and pharmaceutical companies including Sanofi, Novartis, Teva Pharmaceutical Industries and Regeneron Pharmaceuticals contributed data to this initiative, and other potential data donations are currently being pursued. Utilizing the datasets should further encourage collaboration between academic and industry researchers, statisticians and clinicians throughout the world.

"The unique collaborative approach used to create PRO-ACT speaks to the advantages of for-profit, nonprofit and academic centers working together," says Merit Cudkowicz, MD, director of the NCRI and chief of Neurology at MGH. "The PRO-ACT initiative has the power to greatly enhance the design of clinical trials testing new approaches to fight ALS and other challenging neurodegenerative diseases."

The capabilities of the database were put to the test last fall during the DREAM-Phil Bowen ALS Prediction Prize4Life Challenge (http://www.prize4life.org/page/news/10194), in which solvers used a subset of the PRO-ACT dataset to develop algorithms to predict the progress of ALS. The outcome revealed PRO-ACT's benefits increased likelihood of successful trials by providing a tool to measure interpatient variability and the potential to reduce the number of patients needed in a trial by 23 percent.

The Bio-IT World's Best Practices Awards program was established in 2003 to highlight organizations for their outstanding innovations and excellence in the use of technologies and novel business strategies that will advance biomedical and translational research, drug development, and/or clinical trials.


'/>"/>

Contact: Devon Punch
dpunch@partners.org
617-724-7210
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Ivy Neurological Sciences Internship program funded at TGen
2. Kids With Neurological Conditions at Higher Risk of Flu Death: CDC
3. New national clinical trials network for neurological disorders to foster cutting-edge treatments
4. The hidden disorder: Unique treatment proposed for childrens neurological disorder
5. Cedars-Sinai physician-scientist awarded $3M to study most common inherited neurological disorder
6. University Hospitals Neurological Institute to present 6th International 2013 Epilepsy Colloquium
7. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
8. Neurological Wellness Center Pays Tribute to Newly Released Study Announcing TBI Treatment Breakthrough
9. Neurological Wellness Center Posts 700% Sales Increase in 2012; Enters Strategic Alliance with Enbrel Buyer's Club to Provide Low Cost Enbrel
10. NIH clinical trial begins for treatment of rare, fatal neurological disorder
11. New technology may help doctors monitor concussions, aging, and neurological function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... , ... There are nearly 14.5 million people living with and beyond cancer ... June 5, 2016, communities around the world will gather to recognize these cancer survivors ... Survivors Day® is an annual worldwide Celebration of Life that is held on the ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising ... 550 employees of Sun Health Senior Living (SHSL) may not share those ... doctor and prescription copays for the year, while holding the line on increasing their ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... treatment for eating disorders, is opening a brand new child and adolescent residential ... 8-17 and their families with even more specialized eating disorder treatment and access ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic surgeon and ... of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an International Conference ... 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused on stem ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Bunion ... knowns as a bunionette) treatment was more than humbled by customer demand over the ... of their SKU's mid sale. Now that Bunion Bootie has completely replenished its inventory ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... und GERMANTOWN, Maryland , May ... mit Therawis bedient dringenden ... QIAGEN N.V. (NASDAQ: QGEN ... eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH ... Onkologie eingegangen zu sein. Ein erstes Projekt wird ...
(Date:5/25/2016)... , May 25, 2016  Zymo Research Corp. ... their new reference materials that help researchers obtain ... collection to analyses. The rapid growth of the ... researchers to have standard methods to improve the ... Biases inherently exist at every step of the ...
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
Breaking Medicine Technology: